Change Country
Welcome to Spain
Please read the important information below before continuing to our website

The information on this website is published in the UK by Lyxor Asset Management UK LLP (Lyxor UK), which is authorized by Financial Services Authority in the UK, under FSA Registration Number 435658.


The website is hosted by Société Générale, Tours Société Générale, 17 cours Valmy 92987 Paris La Défense (technical team e-mail:


professional client is one of the following:

– an entity required to be authorised or regulated to operate in the financial markets. The following list includes all authorised entities carrying out the characteristic activities of the entities mentioned, whether authorised by an EEA State or a third country and whether or not authorised by reference to a directive:

  • a credit institution
  • an investment firm
  • any other authorised or regulated financial institution
  • an insurance company
  • a collective investment scheme or the management company of such a scheme
  • a pension fund or the management company of a pension fund
  • a commodity or commodity derivatives dealer
  • a local firm
  • any other institutional investor


– in relation to MiFID or equivalent third country business, a large undertaking, meeting two of the following size requirements on a company basis:


  • balance sheet total of EUR 20,000,000
  • net turnover of EUR 40,000,000
  • own funds of EUR 2,000,000


– in relation to business that is neither MiFID or equivalent third country business, a large undertaking meeting either of the following conditions:


  • a body corporate (including a limited liability partnership) which has (or any of whose holding companies or subsidiaries has) called up share capital of at least £10 million (or its equivalent in any other currency at the relevant time);
  • a large undertaking that meets (or any of whose holding companies or subsidiaries meets) two of the following tests: (i) a balance sheet total of EUR 12,500,000; (ii) a net turnover of EUR 25,000,000; (iii) an average number of employees during the year of 250;
  • a national or regional government, a public body that manages public debt, a central bank, an international or supranational institution (such as the World Bank, the IMF, the ECP, the EIB) or another similar international organisation;
  • another institutional investor whose main activity is to invest in financial instruments (in relation to the firm's MiFID or equivalent third country business) or designated investments (in relation to the firm's other business). This includes entities dedicated to the securitisation of assets or other financing transactions.


The above definition is only an extract and is not exhaustive. For further details please refer to the Glossary section of the FSA Handbook:



Marketing Restrictions and Implications


Lyxor UCITS compliant Exchange Traded Funds (Lyxor UCITS ETFs) referred to on this website are open ended mutual investment funds (i) established under the French law and approved by theAutorité des Marchés Financiers (the French Financial Markets Authority), or (ii) established under the Luxembourg law and approved by the Commission de Surveillance du Secteur Financier (the Luxembourg Financial Supervisory Committee). Most, if not all, of the protections provided by theUK regulatory system generally and for UK authorised funds do not apply to these exchange traded funds (ETFs). In particular, investors should note that holdings in this product will not be covered by the provisions of the Financial Services Compensation Scheme, or by any similar scheme in France.


This website is exclusively intended for persons who are not "US persons", as such term is defined in Regulation S or the US Securities Act 1933, as amended, and who are not physically present in the US. This website does not constitute an offer or an invitation to purchase any securities in the United States or in any other jurisdiction in which such offer or invitation is not authorised or to any person to whom it is unlawful to make such offer or solicitation. Potential users of this website are requested to inform themselves about and to observe any such restrictions.



Index Replication Process


Lyxor UCITS ETFs follow both physical and synthetic index replication process.


However, most Lyxor UCITS ETFs follow synthetic replication process. This consists of entering into a derivative transaction (a ‘Performance Swap’, as defined below) with a counterparty that provides complete and effective exposure to its benchmark index. Lyxor has adopted this methodology in order to minimise tracking error, optimise transaction costs and reduce operational risks.


A Performance Swap is a contractual agreement which is negotiated over-the-counter (OTC) between two parties: the Lyxor UCITS ETF and its counterparty. From a risk perspective, each Performance Swap ranks equally with other senior unsecured obligations of the counterparty, such as common bonds (i.e., same rights to payments). In the Performance Swap, the counterparty of the Lyxor UCITS ETF commits to pay the Lyxor UCITS ETF a variable return based on a pre-determined benchmark index, instead of a fixed stream of income (as in bonds). At the same time, the counterparty will receive from the Lyxor UCITS ETF the performance and any related revenues generated by the basket's assets (excluding the value of the Performance Swap) held by the Lyxor UCITS ETF. Information provided on individual ETFs includes data on the basket relating to the ETF and the percentage value of the basket represented by each asset. The information is relevant to the closing values on the date given. 


Investment Risks


The Lyxor UCITS ETFs described on this website are not suitable for everyone. Investors' capital is at risk. Investors should not deal in this product unless they understand, having obtained independent professional advice where necessary, its nature, terms and conditions, and the extent of their exposure to risk. The value of the product can go down as well as up and can be subject to volatility due to factors such as price changes in the underlying instrument and interest rates. If a fund is quoted in a different currency to the index, currency risks exist.


Prior to any investment in any Lyxor UCITS ETF, you should make your own appraisal of the risks from a financial, legal and tax perspective, without relying exclusively on the information provided by us. We recommend that you consult your own independent professional advisors (including legal, tax, financial or accounting advisors, as appropriate).


Specific Risks


Counterparty risk:


Through Lyxor UCITS ETFs, investors are exposed to counterparty risk resulting from the use of OTC swaps with Société Générale. Pursuant to the UCITS Directive 2009/65/EC (as may be amended), the exposure of a UCITS to a swap counterparty which is a credit institution for the purpose of the Directive, cannot exceed 10% of the total fund assets. It is recommended that potential investors study the fund prospectus before investing.


As of 1st January 2013, the long term, senior, unsecured debt obligations of Société Générale were rated A by Standard and Poor’s Ratings Services (S&P) and A2 by Moody’s Investor’s Services Inc (Moody’s). Companies are rated by S&P from AAA (highest rating / most secure) to D (lowest rating / in default / most risky), and by Moody’s from Aaa (highest rating / most secure) to C (lowest rating / in default / most risky).


Liquidity risk:


Société Générale is not the only market-maker for Lyxor UCITS ETFs. Société Générale and any other market makers supporting Lyxor UCITS ETFs on exchange must follow the respective London Stock Exchange (LSE) requirements and guidelines. On-exchange liquidity may be limited as a result of a suspension in the underlying market represented by the index tracked by the ETF; a failure in the LSE, Société Générale or other market-maker systems; or an abnormal trading situation or event.


The securities can be neither offered in nor transferred to the United States.




The tax statement is only a general guide. The tax treatment of investments will depend on an individual’s circumstances. If investors are in any doubt as to their tax position, they must consult with an appropriate professional tax adviser. This statement of the UK tax treatment of the product is based on our understanding of the laws and practice in force as of the date of this document and is subject to any changes in law and the interpretation and application thereof, which changes could be made with retroactive effect.


Further information on the risk factors are available in the Risk Warning section of the website.


Any fund prospectus and supplements are available at Information given about the past performance of the funds is no guarantee of future performance. No investment decision should be taken without reading the fund prospectus and any fund supplement of the fund concerned.


Although the content of the website is based upon information that Lyxor UK and / or Société Générale consider reliable or comes from sources that Lyxor UK and / or Société Générale consider reliable, neither Lyxor UK nor Société Générale have verified such information. Lyxor UK and Société Générale make no representation or warranty as to the accuracy, completeness or adequacy of any information.  Any reproduction, disclosure or dissemination of the materials available on the website is prohibited.




By continuing to browse the site, you are agree on the use of cookies to track the number of visits.To know more about cookies policy:click here


Legal Documents
Factsheets (127)
Prospectus (162)
KIID (161)
Annual Reports (140)
Semi-Annual Reports (142)
Notice to Shareholders (32)
Cotation Document (0)
UKRFS Reports (0)
Notice to Shareholders (0)
Notice to shareholders (0)
Tax data (0)
Statutes (0)
Lyxor Publications
Press Releases (14)
Brochures (6)
Funds Holdings (0)
Lyxor ETF Range (0)
Latest Dividends (0)
Dividends (0)
Investor notices (0)
Customer magazine (0)
Lyxor ETF Product Range (0)
Taxation (0)
Replication information (0)
Press Releases (0)
Product Range (0)
Information about UE regulation N. 236/2012 (0)
Educational fact sheets & brochures (0)
Academic papers (0)
ETF documents (0)
Media articles (0)
Lyxor ETF Barometer (0)
Educational factsheets (0)
Marketing Documents (0)
ETF Publications
Weekly news (80)
ETF trends (39)
Whitepaper (16)
Smart Beta (0)
Brochures (0)
Research (0)
Investment Ideas (0)
Blog (0)

Search result :

764 results
ETF NameISINTypeLanguagePublication DateSizeDownload
MR-Lyxor CAC 40 (DR) UCITS ETFFR0007052782FactsheetsSpanish31 Mar 2017272 Ko
MR-Lyxor China Enterprise (HSCEI) UCITS ETFFR0010204081FactsheetsSpanish31 Mar 2017260 Ko
MR-Lyxor Dow Jones Industrial Average UCITS ETFFR0007056841FactsheetsSpanish31 Mar 2017264 Ko
MR-Lyxor Eastern Europe (CECE NTR EUR) UCITS ETFFR0010204073FactsheetsSpanish31 Mar 2017269 Ko
MR-Lyxor EURO STOXX 50 (DR) UCITS ETFFR0007054358FactsheetsSpanish31 Mar 2017280 Ko
MR-Lyxor FTSE MIB UCITS ETFFR0010010827FactsheetsSpanish31 Mar 2017269 Ko
MR-Lyxor IBEX 35 (DR) UCITS ETFFR0010251744FactsheetsSpanish31 Mar 2017266 Ko
MR-Lyxor Japan (TOPIX) (DR) UCITS ETFFR0010245514FactsheetsSpanish31 Mar 2017264 Ko
MR-Lyxor MSCI AC Asia Pacific Ex Japan UCITS ETFFR0010312124FactsheetsSpanish31 Mar 2017283 Ko
MR-Lyxor MSCI EMU (DR) UCITS ETFFR0007085501FactsheetsSpanish31 Mar 2017280 Ko
MR-Lyxor MSCI EMU Growth UCITS ETFFR0010168765FactsheetsSpanish31 Mar 2017281 Ko
MR-Lyxor MSCI EMU Small Cap UCITS ETFFR0010168773FactsheetsSpanish31 Mar 2017282 Ko
MR-Lyxor MSCI EMU Value UCITS ETFFR0010168781FactsheetsSpanish31 Mar 2017279 Ko
MR-Lyxor MSCI Europe UCITS ETFFR0010261198FactsheetsSpanish31 Mar 2017281 Ko
MR-Lyxor MSCI USA UCITS ETFFR0010296061FactsheetsSpanish31 Mar 2017282 Ko
MR-Lyxor MSCI World UCITS ETFFR0010315770FactsheetsSpanish31 Mar 2017283 Ko
MR-Lyxor NASDAQ-100 UCITS ETFFR0007063177FactsheetsSpanish31 Mar 2017265 Ko
MR-Lyxor Russia (Dow Jones Russia GDR) UCITS ETFFR0010326140FactsheetsSpanish31 Mar 2017247 Ko
MR-Lyxor STOXX Europe 600 Automobiles & Parts UCITS ETFFR0010344630FactsheetsSpanish31 Mar 2017246 Ko
MR-Lyxor STOXX Europe 600 Food & Beverage UCITS ETFFR0010344861FactsheetsSpanish31 Mar 2017255 Ko
MR-Lyxor STOXX Europe 600 Healthcare UCITS ETFFR0010344879FactsheetsSpanish31 Mar 2017255 Ko
MR-Lyxor STOXX Europe 600 Industrial Goods & Services UCITS ETFFR0010344887FactsheetsSpanish31 Mar 2017273 Ko
MR-Lyxor STOXX Europe 600 Technology UCITS ETFFR0010344796FactsheetsSpanish31 Mar 2017255 Ko
MR-Lyxor STOXX Europe 600 Telecommunications UCITS ETFFR0010344812FactsheetsSpanish31 Mar 2017258 Ko
MR-Lyxor STOXX Europe 600 Travel & Leisure UCITS ETFFR0010344838FactsheetsSpanish31 Mar 2017253 Ko